Attached files
| file | filename |
|---|---|
| EX-10.1 - EX-10.1 - AKCEA THERAPEUTICS, INC. | d916784dex101.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 4, 2020
Akcea Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-38137 | 47-2608175 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) | ||
| 22 Boston Wharf Road 9th Floor Boston, MA |
02210 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s Telephone Number, Including Area Code: (617) 207-0202
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common stock | AKCA | NASDAQ |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01 | Entry into a Material Definitive Agreement. |
On January 2, 2020, Michael MacLean, former Chief Financial Officer of Akcea Therapeutics, Inc. (the “Company”) delivered to the Company a 90-day notice of resignation from his position as Chief Financial Officer of the Company. Mr. MacLean’s resignation was effective April 1, 2020.
In connection with the conclusion of his employment with the Company, on April 4, 2020, Mr. MacLean and the Company entered into a separation agreement (the “Separation Agreement”). Under this Separation Agreement, Mr. MacLean will receive medical benefit continuation, and a lump sum severance payment equal to 12 months of his then-current base salary.
The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the copy of such document filed as Exhibit 10.1 to this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 10.1 | Separation Agreement between the Company and Michael MacLean entered into on April 4, 2020. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| AKCEA THERAPEUTICS, INC. | ||||||
| Date: April 9, 2020 | By: | /s/ Joshua F. Patterson | ||||
| Joshua F. Patterson | ||||||
| General Counsel | ||||||